North America Liquid Biopsy Market By Product Type (Assays and Kits, Instruments, and Services), By Application (Early Cancer Detection, Recurrence Monitoring, Prenatal Testing, Organ Transplant Monitoring, and Others), By Biomarker Type (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Microvesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, and Others), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Prenatal Testing, and Others), and By End-User (Hospitals and Clinics, Diagnostic Laboratories, Pharma & Biotech Companies, and Research Institutes), Global Market Size, Segmental analysis, Country Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. North America Liquid Biopsy Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Pediatric liquid biopsy applications address an underserved patient population.

3.2.2. Technological advancements enhance accuracy and reliability of liquid biopsies.

3.2.3. Rising cancer incidence boosts demand for non-invasive diagnostic tools.

3.3. Key industry pitfalls & challenges

3.3.1. Patient preference for traditional biopsies may limit liquid adoption.

3.3.2. High initial development costs hinder smaller clinics' adoption rates.

3.3.3. Technical challenges limit the sensitivity and specificity of liquid biopsies.

3.4. Market Opportunities

3.4.1. Pharma collaborations can drive mutual growth in companion diagnostics.

3.4.2. New biomarker research leads to innovative testing applications and differentiation.

3.4.3. Home testing kits broaden appeal and convenience for consumers.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. North America Liquid Biopsy Market, Product Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Product Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Assays and Kits

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Instruments

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Services

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. North America Liquid Biopsy Market, Application Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Application, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Early Cancer Detection

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Recurrence Monitoring

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Prenatal Testing

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Organ Transplant Monitoring

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Others

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. North America Liquid Biopsy Market, Biomarker Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Biomarker Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Circulating Tumor Cells (CTCs)

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Circulating Tumor DNA (ctDNA)

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Microvesicles

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Others

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. North America Liquid Biopsy Market, Technology Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Technology, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Polymerase Chain Reaction (PCR)

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Next-Generation Sequencing (NGS)

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Microarray

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Others

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. North America Liquid Biopsy Market, Indication Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By Indication, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Lung Cancer

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Breast Cancer

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Colorectal Cancer

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Prostate Cancer

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.6. Pancreatic Cancer

8.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.7. Prenatal testing

8.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.8. Others

8.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. North America Liquid Biopsy Market, End-user Segment Analysis

9.1. Overview

9.1.1. Market Revenue Share, By End-user, 2025 & 2035

9.1.2. Key Market Trends, Growth Factors, & Opportunities

9.2. Hospitals and Clinics

9.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.3. Diagnostic Laboratories

9.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.4. Pharma & Biotech Companies

9.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.5. Research Institutes

9.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

10. North America Liquid Biopsy Market, Region Segment Analysis

10.1. Overview

10.1.1. Global Market Revenue Share, By Region, 2025 & 2035

10.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

10.2. North America

10.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

10.2.2. North America Market Revenue, By Product Type, 2025-2035

10.2.3. North America Market Revenue, By Application, 2025-2035

10.2.4. North America Market Revenue, By Biomarker Type, 2025-2035

10.2.5. North America Market Revenue, By Technology, 2025-2035

10.2.6. North America Market Revenue, By Indication, 2025-2035

10.2.7. North America Market Revenue, By End-user, 2025-2035

10.2.8. The U.S.

10.2.8.1. U.S. Market Revenue, By Product Type, 2025-2035

10.2.8.2. U.S. Market Revenue, By Application, 2025-2035

10.2.8.3. U.S. Market Revenue, By Biomarker Type, 2025-2035

10.2.8.4. U.S. Market Revenue, By Technology, 2025-2035

10.2.8.5. U.S. Market Revenue, By Indication, 2025-2035

10.2.8.6. U.S. Market Revenue, By End-user, 2025-2035

10.2.9. Canada

10.2.9.1. Canada Market Revenue, By Product Type, 2025-2035

10.2.9.2. Canada Market Revenue, By Application, 2025-2035

10.2.9.3. Canada Market Revenue, By Biomarker Type, 2025-2035

10.2.9.4. Canada Market Revenue, By Technology, 2025-2035

10.2.9.5. Canada Market Revenue, By Indication, 2025-2035

10.2.9.6. Canada Market Revenue, By End-user, 2025-2035

11. Company Profile

11.1. Guardant Health, Inc.

11.1.1. Business Overview

11.1.2. Financial Performance

11.1.3. Product/Service Offerings

11.1.4. Strategies & recent developments

11.1.5. SWOT Analysis

11.2. Foundation Medicine, Inc.

11.2.1. Business Overview

11.2.2. Financial Performance

11.2.3. Product/Service Offerings

11.2.4. Strategies & recent developments

11.2.5. SWOT Analysis

11.3. Biocept, Inc.

11.3.1. Business Overview

11.3.2. Financial Performance

11.3.3. Product/Service Offerings

11.3.4. Strategies & recent developments

11.3.5. SWOT Analysis

11.4. Freenome Holdings, Inc.

11.4.1. Business Overview

11.4.2. Financial Performance

11.4.3. Product/Service Offerings

11.4.4. Strategies & recent developments

11.4.5. SWOT Analysis

11.5. Cynvenio Biosystems, Inc.

11.5.1. Business Overview

11.5.2. Financial Performance

11.5.3. Product/Service Offerings

11.5.4. Strategies & recent developments

11.5.5. SWOT Analysis

11.6. NeoGenomics Laboratories, Inc.

11.6.1. Business Overview

11.6.2. Financial Performance

11.6.3. Product/Service Offerings

11.6.4. Strategies & recent developments

11.6.5. SWOT Analysis

11.7. Exosome Diagnostics, Inc.

11.7.1. Business Overview

11.7.2. Financial Performance

11.7.3. Product/Service Offerings

11.7.4. Strategies & recent developments

11.7.5. SWOT Analysis

11.8. Personal Genome Diagnostics (PGDx)

11.8.1. Business Overview

11.8.2. Financial Performance

11.8.3. Product/Service Offerings

11.8.4. Strategies & recent developments

11.8.5. SWOT Analysis

11.9. Strata Oncology, Inc.

11.9.1. Business Overview

11.9.2. Financial Performance

11.9.3. Product/Service Offerings

11.9.4. Strategies & recent developments

11.9.5. SWOT Analysis

11.10. Trovagene, Inc.

11.10.1. Business Overview

11.10.2. Financial Performance

11.10.3. Product/Service Offerings

11.10.4. Strategies & recent developments

11.10.5. SWOT Analysis

11.11. GRAIL, Inc.

11.11.1. Business Overview

11.11.2. Financial Performance

11.11.3. Product/Service Offerings

11.11.4. Strategies & recent developments

11.11.5. SWOT Analysis

11.12. Chronix Biomedical, Inc.

11.12.1. Business Overview

11.12.2. Financial Performance

11.12.3. Product/Service Offerings

11.12.4. Strategies & recent developments

11.12.5. SWOT Analysis

11.13. Liquid Biopsy, Inc.

11.13.1. Business Overview

11.13.2. Financial Performance

11.13.3. Product/Service Offerings

11.13.4. Strategies & recent developments

11.13.5. SWOT Analysis

11.14. OncoOne, Inc.

11.14.1. Business Overview

11.14.2. Financial Performance

11.14.3. Product/Service Offerings

11.14.4. Strategies & recent developments

11.14.5. SWOT Analysis

11.15. MediSapiens

11.15.1. Business Overview

11.15.2. Financial Performance

11.15.3. Product/Service Offerings

11.15.4. Strategies & recent developments

11.15.5. SWOT Analysis